Show simple item record

dc.contributor.authorPurtill, D
dc.contributor.authorAntonenas, V
dc.contributor.authorChiappini, P
dc.contributor.authorTong, D
dc.contributor.authorO'Flaherty, E
dc.contributor.authorBajel, A
dc.contributor.authorKabani, K
dc.contributor.authorLarsen, S
dc.contributor.authorTan, S
dc.contributor.authorHutchins, C
dc.contributor.authorCurtis, DJ
dc.contributor.authorKennedy, GA
dc.contributor.authorWatson, A-M
dc.contributor.authorBai, L
dc.contributor.authorGreenwood, M
dc.contributor.authorGottlieb, DJ
dc.contributor.authorHamad, N
dc.date.accessioned2020-12-14T06:34:18Z
dc.date.available2020-12-14T06:34:18Z
dc.date.issued2020-09-08
dc.identifierpii: S2473-9529(20)31177-0
dc.identifier.citationPurtill, D., Antonenas, V., Chiappini, P., Tong, D., O'Flaherty, E., Bajel, A., Kabani, K., Larsen, S., Tan, S., Hutchins, C., Curtis, D. J., Kennedy, G. A., Watson, A. -M., Bai, L., Greenwood, M., Gottlieb, D. J. & Hamad, N. (2020). Variable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. BLOOD ADVANCES, 4 (17), pp.4147-4150. https://doi.org/10.1182/bloodadvances.2020002431.
dc.identifier.issn2473-9529
dc.identifier.urihttp://hdl.handle.net/11343/254259
dc.description.abstractDonor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34+ cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34+ cell viability. We conclude that although postthaw CD34+ cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients.
dc.languageEnglish
dc.publisherAMER SOC HEMATOLOGY
dc.titleVariable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic
dc.typeJournal Article
dc.identifier.doi10.1182/bloodadvances.2020002431
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBlood Advances
melbourne.source.volume4
melbourne.source.issue17
melbourne.source.pages4147-4150
melbourne.elementsid1466027
melbourne.openaccess.urlhttp://doi.org/10.1182/bloodadvances.2020002431
melbourne.openaccess.statusPublished version
melbourne.contributor.authorCurtis, David
dc.identifier.eissn2473-9537
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record